Vertex Pharmaceuticals Incorporated revealed the progression of inaxaplin (VX-147) to the critical Phase 3 segment of the worldwide Phase 2/3 clinical study focusing on APOL1-related renal conditions.

TransCon PTH, developed by Ascendis Pharma, is an investigational prodrug of PTH hormone undergoing research and development.

Asha Therapeutics has revealed its selection of an innovative internal-binding compound, designated ASHA-624, intended as a treatment agent to alter the progression of Amyotrophic Lateral Sclerosis.

A drug interaction occurs when two or more drugs interact in the body, affecting the efficacy or safety of one or both medications.

The U.S. authorities have endorsed the review of a licensing request for Datopotamab Deruxtecan.

IASO Bio has disclosed official authorization from the China National Medical Products Administration for the clinical trial application of Equecabtagene Autoleucel.

Bristol Myers Squibb Reveals Key Outcomes from KRYSTAL-12 Study on KRAZATI (adagrasib) Demonstrating Main Goal of Halting Disease Progress in Advanced KRASG12C-Altered Non-Small Cell Lung Cancer.

The EU Commission has approved the use of Merck's drug KEYTRUDA® (pembrolizumab) in combination with chemotherapy as a first treatment.

Encouraging initial human trial Phase 1B results for VRON-0200, an innovative checkpoint modifier for Chronic Hepatitis B, were showcased as a late-breaking entry at the APASL 2024 Global Liver Conference.

Drug monitoring, in the context of healthcare and pharmacology, refers to the process of tracking and evaluating the use, safety, efficacy, and overall impact of medications in clinical practice.

Biond Biologics reveals at the 2024 AACR Annual Meeting, the introduction of their pioneering anti-ILT3 antibody, BND-35, designed to transform the tumor microenvironment.

Idiopathic Pulmonary Fibrosis (IPF) is a progressive lung condition causing scarring and stiffness, which makes breathing harder over time.